Date published: 2025-12-6

1-800-457-3801

SCBT Portrait Logo
Seach Input

Benazeprilat (CAS 86541-78-8)

5.0(1)
Write a reviewAsk a question

See product citations (1)

Alternate Names:
USP Benazepril Related Compound C
Application:
Benazeprilat is a potent ACE inhibitor
CAS Number:
86541-78-8
Molecular Weight:
396.44
Molecular Formula:
C22H24N2O5
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

Benazeprilat is an organic compound that serves as the active metabolite of benazepril. It is characterized by its role in the biochemical processes involving the inhibition of certain enzymes. Structurally, benazeprilat contains both carboxyl (-COOH) and tetrahydroisoquinoline components, contributing to its unique chemical properties and interactions at the molecular level. Benazeprilat is primarily studied and utilized in research applications for its interactions with enzyme systems. It is of particular interest in the field of biochemistry for studies on enzyme inhibition, where understanding the mode of action and effects of such compounds can elucidate the mechanisms of enzyme function and regulation. Researchers may also explore the kinetics of benazeprilat′s interaction with its target enzymes, investigating parameters such as inhibition constants, binding affinity, and the impact of structural modifications on activity.


Benazeprilat (CAS 86541-78-8) References

  1. Plasma angiotensin converting enzyme activity and pharmacokinetics of benazepril and benazeprilat in cats after single and repeated oral administration of benazepril.HCl.  |  King, JN., et al. 1999. J Vet Pharmacol Ther. 22: 360-7. PMID: 10651464
  2. Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamic modeling approach.  |  Toutain, PL., et al. 2000. J Pharmacol Exp Ther. 292: 1087-93. PMID: 10688627
  3. Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats.  |  King, JN., et al. 2003. J Vet Pharmacol Ther. 26: 213-24. PMID: 12755906
  4. An angiotensin converting enzyme inhibitor, benazepril can be transformed to an active metabolite, benazeprilat, by the liver of dogs with ascitic pulmonary heartworm disease.  |  Kitagawa, H., et al. 2003. J Vet Med Sci. 65: 701-6. PMID: 12867730
  5. Pharmacokinetics and pharmacokinetic/pharmacodynamic relationships for angiotensin-converting enzyme inhibitors.  |  Toutain, PL. and Lefèbvre, HP. 2004. J Vet Pharmacol Ther. 27: 515-25. PMID: 15601445
  6. Simultaneous determination of benazepril hydrochloride and benazeprilat in plasma by high-performance liquid chromatography/electrospray-mass spectrometry.  |  Xiao, W., et al. 2005. J Chromatogr B Analyt Technol Biomed Life Sci. 814: 303-8. PMID: 15639452
  7. Development and validation of a liquid chromatographic/electrospray ionization mass spectrometric method for the determination of benazepril, benazeprilat and hydrochlorothiazide in human plasma.  |  Vonaparti, A., et al. 2006. J Mass Spectrom. 41: 593-605. PMID: 16541390
  8. Simultaneous and rapid quantitation of benazepril and benazeprilat in human plasma by high performance liquid chromatography with ultraviolet detection.  |  Wang, XD., et al. 2007. J Pharm Biomed Anal. 44: 224-30. PMID: 17289327
  9. Hemodynamic effects of benazeprilat in the anesthetized dog with acute left ventricular failure.  |  Nakazawa, M., et al. 1991. Jpn J Pharmacol. 56: 369-75. PMID: 1895581
  10. Simultaneous determination of lercanidipine, benazepril and benazeprilat in plasma by LC-MS/MS and its application to a toxicokinetics study.  |  Chen, K., et al. 2012. J Chromatogr B Analyt Technol Biomed Life Sci. 899: 1-7. PMID: 22622066
  11. Development, optimization and validation of a highly sensitive UPLC-ESI-MS/MS method for simultaneous quantification of amlodipine, benazeprile and benazeprilat in human plasma: application to a bioequivalence study.  |  Rezk, MR. and Badr, KA. 2014. J Pharm Biomed Anal. 98: 1-8. PMID: 24863555
  12. Hemodynamic effects of amlodipine and benazeprilat in spontaneously hypertensive rats.  |  Bazil, MK. and Webb, RL. 1993. J Cardiovasc Pharmacol. 21: 405-11. PMID: 7681501
  13. Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs.  |  King, JN., et al. 1995. Am J Vet Res. 56: 1620-8. PMID: 8599524
  14. Amlodipine and benazeprilat differently affect the responses to endothelin-1 and bradykinin in porcine ciliary arteries: effects of a low and high dose combination.  |  Lang, MG., et al. 1997. Curr Eye Res. 16: 208-13. PMID: 9088736

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

Benazeprilat, 5 mg

sc-217710
5 mg
$340.00